主页 > 医学文档 >
【medical-news】ACEI或ARB可降低皮肤癌发病风险
Evidence from in vivo and in vitro studies suggests that angiotensin II is a potent angiogenic and growth factor, Dr. Jennifer B. Christian and co-investigators note in the September 3 Journal of the National Cancer Institute, issued online on August 26. There are also indications from epidemiological research that ACE inhibitors and ARBs may protect against cancer.
To examine the effect of these drugs on the risk of keratinocyte skin cancers, the research team analyzed data from a Department of Veterans Affairs trial of topical tretinoin involving 1051 patients deemed to be at high risk of basal cell or squamous cell carcinoma, based on the occurrence of two tumors in the 5 years preceding enrollment between 1998 and 2003.
All subjects were free of cancer at baseline. Approximately half (532) had been prescribed an ACE inhibitor or ARB during the trial or the 3 months prior to enrollment.
A total of 472 basal cell carcinomas and 309 squamous cell carcinomas were diagnosed during a median follow-up of 3.4 years. The combined absolute incidence rates per 1000 person-years were 237 among users of ACE inhibitors/ARBs and 374 among nonusers.
"We were surprised to find such a pronounced reduction in BCC and SCC incidence in users of ACE inhibitor or ARBs in such a high-risk group over a short amount of time," Dr. Christian at Brown University in Providence, Rhode Island, and her associates write.
Compared with nonusers, users of ACE inhibitors or ARBs were at significantly reduced risk of basal cell carcinoma (incidence rate ratio 0.61) and of squamous cell carcinoma (IRR 0.67). The greatest reductions were observed when ACE inhibitors or ARBs were initiated during the study period (IRRs 0.45 and 0.48, respectively), implying "a more immediate effect rather than a delayed effect."
"If these novel findings are confirmed in a randomized controlled trial, they may lead to prevention of these very common cancers, at least among individuals at very high risk."
J Natl Cancer Inst 2008;100:1223-1232. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 NEW YORK (Reuters Health) Aug 28 - Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) appears to lower the incidence of basal cell and squamous cell carcinoma among people at high risk, according to a study among US veterans.
纽约（路透社 健康）8月28日-研究表明，使用血管紧张素转换酶（ACE）抑制剂或血管紧张度受体阻断剂（ARBs）能降低基底细胞癌和鳞状上皮细胞癌在高危人群中的发病率。
Evidence from in vivo and in vitro studies suggests that angiotensin II is a potent angiogenic and growth factor, Dr. Jennifer B. Christian and co-investigators note in the September 3 Journal of the National Cancer Institute, issued online on August 26. There are also indications from epidemiological research that ACE inhibitors and ARBs may protect against cancer.
Dr. Jennifer B. Christian和他的同僚们在9月3日的国立癌症研究所登记并在8月26日发表在网络上，根据在体研究和体外研究提示血管紧张素II是一种有效的血管源性的生长因子。同时，流行病学研究也表明ACEI和ARBs可能具有抗癌作用。
To examine the effect of these drugs on the risk of keratinocyte skin cancers, the research team analyzed data from a Department of Veterans Affairs trial of topical tretinoin 编译：
纽约（路透社 健康）8月28日-研究表明，使用血管紧张素转换酶（ACE）抑制剂或血管紧张度受体阻断剂（ARBs）能降低基底细胞癌和鳞状上皮细胞癌在高危人群中的发病率。
Dr. Jennifer B. Christian和他的同僚们在9月3日的国立癌症研究所登记并在8月26日发表在网络上，根据在体研究和体外研究提示血管紧张素II是一种有效的血管源性的生长因子。同时，流行病学研究也表明ACEI和ARBs可能具有抗癌作用。
为了检测这些药物在降低角质化皮肤癌的发病率的作用，研究团队分析了来自于退伍事物部门的局部维甲酸的试验，这项试验包括1051位被认为具有基底细胞癌或鳞状上皮细胞癌高发病率的患者，基于在1998年和2003年之间登记的这两种癌症的发生情况。
所有的受试者均为免费检测癌症基线。大约一般的人（532人）在试验期间或登记之前的3个月服用过ACEI或ARB。
在接下去的中位数为3.4年的随访中，总共有472人被诊断为基底细胞癌，309人被诊断为鳞状上皮细胞癌。结合起来的总的绝对发病率为每1000个人/年中有237人使用ACEI/ARB的被诊断为癌症，而不服用ACEI/ARB的有374人被诊断为癌症。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-08 05:11
医学,生命科学网